Represents the amortization of capitalized fees paid to a related party.

No definition available.

Name:	inva_AmortizationOfCapitalizedFeesPaidToRelatedParty
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise and net of capitalized fees paid to a related party.

+ References

No definition available.

+ Details

Name:	inva_RevenueFromContractWithCustomerExcludingAssessedTaxNetOfAmortizationOfCapitalizedFeesPaidToRelatedParty
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 32
-Paragraph 2A
-URI http://asc.fasb.org/extlink&oid=82859839&loc=SL82860478-203043

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130543-203045

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130539-203045

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.1(c))
-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999

+ Details

Name:	us-gaap_RevenueFromRelatedParties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ProductOrServiceAxis=inva_RoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=inva_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=inva_LABACollaborationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=inva_TrelegyElliptaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=inva_StrategicAllianceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue Recognition and Collaborative Arrangements (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue Recognition and Collaborative Arrangements
Total net revenue	$ 67,086	$ 58,562	$ 119,466	$ 99,054
Royalty Revenue
Revenue Recognition and Collaborative Arrangements
Less: amortization of capitalized fees paid to a related party	(3,456)	(3,456)	(6,912)	(6,912)
Royalty revenue	67,086	58,341	119,466	98,612
License
Revenue Recognition and Collaborative Arrangements
Strategic alliance - MABA program license	0	221	0	442
GSK
Revenue Recognition and Collaborative Arrangements
Total net revenue			119,466	99,054
Long-acting beta agonist (LABA) collaboration \| Royalty Revenue
Revenue Recognition and Collaborative Arrangements
Royalties from a related party	70,542	61,797
Less: amortization of capitalized fees paid to a related party	(3,456)	(3,456)
Royalty revenue	67,086	58,341
Long-acting beta agonist (LABA) collaboration \| RELVAR/BREO
Revenue Recognition and Collaborative Arrangements
Royalties from a related party	57,515	54,645
Long-acting beta agonist (LABA) collaboration \| ANORO
Revenue Recognition and Collaborative Arrangements
Royalties from a related party	10,656	7,152
Long-acting beta agonist (LABA) collaboration \| TRELEGY
Revenue Recognition and Collaborative Arrangements
Royalties from a related party	2,371	0
Long-acting beta agonist (LABA) collaboration \| GSK \| Royalty Revenue
Revenue Recognition and Collaborative Arrangements
Royalties from a related party			126,378	105,524
Less: amortization of capitalized fees paid to a related party			(6,912)	(6,912)
Royalty revenue			119,466	98,612
Long-acting beta agonist (LABA) collaboration \| GSK \| RELVAR/BREO
Revenue Recognition and Collaborative Arrangements
Royalties from a related party			103,675	93,334
Long-acting beta agonist (LABA) collaboration \| GSK \| ANORO
Revenue Recognition and Collaborative Arrangements
Royalties from a related party			19,380	12,190
Long-acting beta agonist (LABA) collaboration \| GSK \| TRELEGY
Revenue Recognition and Collaborative Arrangements
Royalties from a related party			3,323	0
Strategic alliance - MABA program license \| License
Revenue Recognition and Collaborative Arrangements
Strategic alliance - MABA program license	$ 0	$ 221
Strategic alliance - MABA program license \| GSK \| License
Revenue Recognition and Collaborative Arrangements
Strategic alliance - MABA program license			$ 0	$ 442